07:00 , Jul 15, 2002 |  BC Week In Review  |  Clinical News

NCX 950: Phase I/II

In a double-blind, placebo-controlled, cross-over Swiss Phase I/II study in 24 volunteers, single doses of NCX 950 were safe and well tolerated. NCX 950 was equipotent compared to inhaled salbutamol sulphate in inducing bronchodilation, but...
08:00 , Nov 12, 2001 |  BC Week In Review  |  Clinical News

AeroDose albuterol: Phase II

AEGN said results of a U.K. Phase II trial showed comparable improvement in lung function using AEGN's Aerodose albuterol inhaler delivering 10%-20% of the standard dose of drug compared to a jet nebulizer delivering the...
07:00 , Sep 24, 2001 |  BC Week In Review  |  Clinical News

: Phase II results; Phase III

Results of a Phase II study of (R,R)-formoterol in 340 patients showed that patients given study drug had improvements in FEV1 of 24%-27%, which was superior to placebo (p<0.001). Effects lasted up to 24 hours....
08:00 , Jan 16, 2001 |  BC Week In Review  |  Clinical News

AeroDose albuterol: Began Phase II testing

AeroGen Inc. (AEGN), Sunnyvale, Calif.   Product: AeroDose albuterol   Business: Drug delivery   Therapeutic category: Receptor antagonist   Target: Beta adrenergic receptors   Description: Inhaled albuterol using AEGN's AeroDose aerosol inhaler   Indication: Treat...
08:00 , Dec 20, 1999 |  BC Week In Review  |  Clinical News

Esprolol: Phase IIb

In a Phase IIb study, esprolol gave a significant improvement in exercise parameters including exercise duration and time to onset of angina pain and ischemia compared to placebo when given 30 or 120 minutes prior...
07:00 , Jun 28, 1999 |  BC Week In Review  |  Clinical News

Esprolol: Began Phase IIb study

Selectus Pharmaceuticals Inc., West Conshohocken, Penn.   Product: Esprolol   Business: Cardiovascular   Therapeutic category: Receptor antagonist   Target: Beta adrenergic receptors   Description: Sublingual beta-blocker   Indication: Treat angina pectoris   Status: Selectus began...
07:00 , May 3, 1999 |  BC Week In Review  |  Clinical News

: Phase IIa

Data from a 49-patient dose-ranging crossover study showed that higher doses of (R,R)-formoterol produced a statistically significant improvement in forced expiratory volume in one second (FEV1) compared to Glaxo Wellcome's Ventolin albuterol or placebo (p<0.05)...